Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (Nasdaq: WVE) regained full rights to WVE-006, an investigational GalNAc-conjugated RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), and will accelerate its registrational strategy.
Wave plans FDA engagement on a potential accelerated approval pathway with regulatory feedback expected mid-2026. RestorAATion-2 400 mg multidose data remain on track for Q1 2026; 600 mg single and multidose cohort data are expected in 2026. The research collaboration with GSK expanded with a fourth program selected; Wave is eligible for up to $2.8 billion in milestones. Wave expects cash runway into 3Q 2028.
Wave Life Sciences (Nasdaq: WVE) outlined 2026 priorities: accelerate development of WVE-007 (INHBE GalNAc-siRNA) for obesity and advance its RNA editing portfolio. Wave plans a Phase 2a multidose start in 1H 2026, new add-on and post-incretin WVE-007 trials in 2026, and near-term single-dose follow-ups (three-month 400 mg and six-month 240 mg data) expected in Q1 2026. Wave reported single-dose 240 mg data showing fat loss similar to GLP-1 at three months with muscle preservation. RNA editing progress includes RestorAATion-2 updates and a planned WVE-008 CTA filing in 2026. Preliminary cash ~$602M, runway into 3Q 2028. Presentation at J.P. Morgan Jan 13, 2026.
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived on the site for a limited time after the presentation.
Wave Life Sciences (Nasdaq: WVE) priced an underwritten public offering to raise gross proceeds of approximately $350 million.
The offering consists of 15,789,475 ordinary shares at $19.00 per share and, in lieu of shares to certain investors, 2,631,578 pre-funded warrants at $18.9999 each (exercise price $0.0001). Wave granted the underwriters a 30-day option to buy up to an additional 2,763,157 shares. The offering is expected to close on or about December 11, 2025, subject to customary conditions.
Wave Life Sciences (Nasdaq: WVE) commenced an underwritten public offering to raise $250 million of ordinary shares and, for certain investors electing that option, pre-funded warrants to purchase ordinary shares on Dec. 8, 2025.
The company granted the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares and shares underlying pre-funded warrants. Jefferies, Leerink Partners and BofA Securities are joint book-running managers. The offering is subject to market and other conditions and will be made only by prospectus and prospectus supplement filed with the SEC.
Wave Life Sciences (Nasdaq: WVE) reported positive interim Phase 1 INLIGHT data for WVE-007 (INHBE) after a single 240 mg subcutaneous dose in individuals with mean baseline BMI ~32 kg/m2.
At Day 85, WVE-007 produced a 9.4% visceral fat reduction (p=0.02), 4.5% total body fat reduction (3.5 lbs; p=0.07), and a 3.2% lean mass increase (4.0 lbs; p=0.01). Mean Activin E fell >75% and maxed at 78% reduction, supporting once- or twice-yearly dosing. Safety was generally favorable up to 600 mg with no serious TEAEs. Phase 2 planning is underway; further 2026 follow-ups expected.
Wave Life Sciences (Nasdaq: WVE) will announce interim data from the ongoing Phase 1 INLIGHT trial of WVE-007 (INHBE) for obesity on Monday, December 8, 2025. A press release will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. Investors can access the live webcast via the company’s Investor Events page and an archived version will be available after the event.
This announcement covers timing and access for interim clinical data disclosure for WVE-007; no trial results or financial metrics are included in this notice.
Wave Life Sciences (Nasdaq: WVE) reported Q3 2025 results and pipeline updates on Nov 10, 2025. Key clinical readouts: WVE-007 (INHBE GalNAc-siRNA) produced dose-dependent Activin E reductions up to 85% at Day 29 with lowest-dose durability through six months, supporting once- or twice-year dosing; WVE-006 (AIMer for AATD) achieved AAT protein > 20 µM during acute response, basal AAT ~13 µM, wild-type M-AAT ~64% of serum AAT, and Z-AAT reduced by 60%. Cash was $196.2M at Sept 30, 2025, and subsequent $72.1M ATM proceeds plus committed GSK milestones extend runway into 2Q 2027. Multiple clinical data updates and regulatory filings expected through 2026, including WVE-N531 NDA planning and WVE-008 CTA filing.
Wave Life Sciences (Nasdaq: WVE) announced that management will participate in two investor conferences in November 2025.
Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, President and CEO, will speak in an analyst-led fireside chat on Tuesday, November 11, 2025 at 10:00 a.m. ET.
Jefferies London Healthcare Conference — Dr. Bolno will join an analyst-led fireside chat on Thursday, November 20, 2025 at 8:30 a.m. GMT / 3:30 a.m. ET and participate in an Anti-Obesity Panel at 9:00 a.m. GMT / 4:00 a.m. ET. Live webcasts and limited-time replays are available via the company’s Investors "Investor Events" page.
Wave Life Sciences (NASDAQ: WVE) will present preclinical data for WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek® on November 6, 2025, showing a potential approach to drive fat loss while preserving muscle with once- or twice-yearly dosing.
Key preclinical findings: single-dose weight loss in DIO mice, visceral adipose reductions, adipocyte shrinkage, fewer pro-inflammatory macrophages (up to 80%), reduced fibrosis (58%), and doubled weight loss when combined with semaglutide. Early clinical INLIGHT results show dose-dependent Activin E decreases of 56–85% at Day 29 and durable reductions through six months; WVE-007 was reported as safe and well tolerated to date.